Status:
NOT_YET_RECRUITING
Dietary Supplements in Patients With Coronary Artery Bypass Grafting for Improving the Quality of Healthcare Delivery.
Lead Sponsor:
Nicosia General Hospital
Collaborating Sponsors:
University of Cyprus
AVVA Pharmaceuticals Ltd.
Conditions:
Cardio-pulmonary Bypass
Cardiovascular Diseases
Eligibility:
All Genders
40-80 years
Phase:
NA
Brief Summary
Cardiovascular disease (CVD) remains the leading cause of death worldwide. Prevention of CAD by targeting modifiable factors remains a key public health priority. L-Ascorbic Acid (Vitamin C - Vit. C) ...
Detailed Description
Background: Cardiovascular disease (CVD) remains the leading cause of death worldwide. CVD is the result of disorders of the heart and blood vessels and includes cerebrovascular disease, coronary arte...
Eligibility Criteria
Inclusion
- The subjects will be people 40-80 years old, with coronary artery disease, and mental clarity who will undergo Coronary Aortic Bypass (CABG) in our clinic (Public Cardiothoracic Surgery clinic in Nicosia General Hospital) and will be randomized into 2 groups (intervention group and control group).
- Signed consent form
- Ability to adhere to the protocol
Exclusion
- Any psychiatric, neurological or motor disorder.
- Hypersensitivity to the components of the supplement.
- Combined Cardiac Surgery other than CABG and valve or aortic
- Concurrent participation in other clinical trials.
- Previous use of any probiotics, prebiotics, adsorbent dietary supplements, Vitamin C and/or Omega 3 fatty acids.
Key Trial Info
Start Date :
September 1 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 1 2028
Estimated Enrollment :
108 Patients enrolled
Trial Details
Trial ID
NCT06995586
Start Date
September 1 2025
End Date
September 1 2028
Last Update
May 29 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Nicosia General Hospital
Stróvolos, Nicosia, Cyprus, 2031